CIK 0000882796
- Large accelerated filer
BIOCRYST PHARMACEUTICALS INC
Sign in to watch- Ticker
- BCRX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 621413174
- Phone
- +1 919-859-1302
- Business address
- 4505 EMPEROR BOULEVARD, SUITE 200, DURHAM, NC, 27703
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2017-03-08 | STAAB THOMAS R II Senior Vice President and CFO | Sale | −3,250 | $8.20 | $27K | 120,563 |
| 2017-03-08 | STAAB THOMAS R II Senior Vice President and CFO | Sale | −3,250 | $8.65 | $28K | 117,313 |
| 2017-03-08 | STAAB THOMAS R II Senior Vice President and CFO | Exercise or conversion · Emp. Stock Option (Right to Buy) | −6,500 | 86,260 | ||
| 2017-03-06 | STAAB THOMAS R II Senior Vice President and CFO | Exercise or conversion | +3,250 | $3.78 | $12K | 120,563 |
| 2017-03-06 | STAAB THOMAS R II Senior Vice President and CFO | Sale | −3,250 | $7.90 | $26K | 117,313 |
| 2017-03-06 | STAAB THOMAS R II Senior Vice President and CFO | Exercise or conversion · Emp. Stock Option (Right to Buy) | −3,250 | 92,760 | ||
| 2017-03-02 | INGRAM ROBERT ALEXANDER Director | Grant or award | +1,602 | $6.24 | $10K | 5,823 |
| 2017-03-01 | Hutson Nancy J Director | Grant or award | +1,602 | $6.24 | $10K | 30,266 |
| 2017-03-01 | Cohen Fred E Director | Grant or award | +1,602 | $6.24 | $10K | 117,469 |
| 2017-02-27 | Powell Lynne Senior VP - CCO | Grant or award · Emp. Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2017-02-27 | Barnes Alane P VP, General Counsel & Corp Sec | Grant or award · Emp. Stock Option (Right to Buy) | +150,000 | 150,000 | ||
| 2017-02-27 | Babu Yarlagadda S Senior VP - Drug Discovery | Grant or award · Emp. Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2017-02-27 | Sheridan William P Senior VP - CMO | Grant or award · Emp. Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2017-02-27 | STAAB THOMAS R II Senior Vice President and CFO | Grant or award · Emp. Stock Option (Right to Buy) | +175,000 | 175,000 | ||
| 2017-02-27 | Stonehouse Jon P President & CEO | Grant or award · Emp. Stock Option (Right to Buy) | +500,000 | 500,000 | ||
| 2017-01-20 | Barnes Alane P VP, General Counsel & Corp Sec | Shares withheld for taxes | −2,599 | $5.95 | $15K | 75,497 |
| 2017-01-20 | Babu Yarlagadda S Senior VP - Drug Discovery | Shares withheld for taxes | −5,083 | $5.95 | $30K | 104,706 |
| 2017-01-20 | Sheridan William P Senior VP - CMO | Shares withheld for taxes | −5,761 | $5.95 | $34K | 82,916 |
| 2017-01-20 | STAAB THOMAS R II Senior Vice President and CFO | Shares withheld for taxes | −5,198 | $5.95 | $31K | 117,313 |
| 2017-01-20 | Stonehouse Jon P President & CEO | Shares withheld for taxes | −10,572 | $5.95 | $63K | 645,418 |
Page 41 of 45 · 882 trades